32 results about "Bile-acid Binding Resin" patented technology

A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

An ester formed from an inositol or an inositol derivative and niacin, wherein the inositol or the inositol derivatives comprises a stereoisomer selected from allo-inositol, cis-inositol, epi-inositol, muco-inositol, neo-inositol, scyllo-inositol, D-chiro-inositol and L-chiro-inositol, or pharmaceutically acceptable salts thereof. Examples of esters include inositol hexaniacinates such as allo-inositol hexaniacinate and cis-inositol hexaniacinate. The esters can be used to treat any disorder that is treatable with niacin therapy such as dyslipidemia, hypercholesterolemia, hyperlipidemia or cardiovascular disease. The esters can be administered with other agents such as HMG-CoA reductase inhibitors, statins, fibrates, activators of peroxisome proliferator activated receptors policosanol, phytosterols, tocotrienols, calcium, bile acid sequestrants, guar gum and free niacin. The invention includes pharmaceutical compositions containing these compounds.

Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in combination are also disclosed.

Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co- administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in combination are also disclosed.

The invention relates to a biocompatible bile acid sequestrant and its preparation method and application. The preparation method steps are as follows: (1) N-hexylallylamine is added dropwise in hydrochloric acid to obtain N-hexylallylamine hydrochloride; (2) N-hexylallylamine hydrochloride aqueous solution and Allylamine hydrochloride aqueous solution is mixed uniformly, adding initiator, polymerization reaction, obtains polymer precursor; (3) methyl-α-D-glucopyranoside is dissolved in deionized water, adds oxidizing agent, avoids photoreaction to prepare a dialdehyde crosslinking agent; (4) adding a dialdehyde crosslinking agent solution to the polymer precursor aqueous solution, stirring and mixing, and standing at room temperature for reaction to prepare a biocompatible bile acid chelating agent. In the preparation method of the present invention, the cross-linking agent only uses the biocompatible dialdehyde cross-linking agent obtained by oxidizing glycosides. In addition, no other toxic cross-linking agents are used, which has good biocompatibility and reduces risks of in vivo application.

The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.

The present invention provides a method for treatment of high cholesterol by reducing low density lipoprotein cholesterol (LDL-C) and / or very low density Opoproiein cholesterol (VLDL-C) in subjects In need thereof by administering a compound that inhibits HIF hydroxylase activity. The method is useful, for reducing LDL cholesterol levels and total cholesterol levels even In subjects already undergoing treatment with other cholesterol-lowering medications, for example statins, fibrates, nicotinic acids and bile acid-binding resins, and in patients having chronic kidney disease or end stage renal disease, inter alia.

The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount.The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.

The invention relates to the field of medicine, and specifically discloses an enteric-coated gastro-retentive oral dosage form in tablet form, and applications and a pharmaceutical composition thereof. The oral dosage form includes: a. a bile acid chelating agent selected from colesevelam and colesevelam hydrochloride; b. a polymeric matrix comprising a poly(alkylene), the bile acid chelating agent being dispersed in the polymeric matrix; c. one or more fillers or compression agents selected from microcrystalline cellulose, lactose, starch, maltodextrin, and dicalcium phosphate, wherein the oral dosage form slowly releases the bile acid chelating agent into a stomach. The dosage form is capable of providing the bile acid chelating agent to the stomach in long-lasting and stable level, theconcentration of the bile acid chelating agent permitting the bile acid chelating agent to optimally combine with bile acids refluxing from a small intestine to the stomach, thereby avoiding damages of a gastric mucosa caused by bile acids, and preventing the bile acids in the stomach from refluxing to an esophagus and other parts of an upper digestive tract and a throat, to prevent further damage.